|
|
Volumn 370, Issue 18, 2014, Pages 1769-1770
|
|
Overall survival in renal-cell carcinoma with pazopanib versus sunitinib
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PAZOPANIB;
SUNITINIB;
ANGIOGENESIS INHIBITOR;
INDOLE DERIVATIVE;
PYRIMIDINE DERIVATIVE;
PYRROLE DERIVATIVE;
SULFONAMIDE;
ANTIANGIOGENIC ACTIVITY;
CLEAR CELL CARCINOMA;
DRUG SAFETY;
HUMAN;
INTENTION TO TREAT ANALYSIS;
KARNOFSKY PERFORMANCE STATUS;
KIDNEY CARCINOMA;
LETTER;
MAJOR CLINICAL STUDY;
NEPHRECTOMY;
OVERALL SURVIVAL;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
SCORING SYSTEM;
UNSPECIFIED SIDE EFFECT;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE FREE SURVIVAL;
FOLLOW UP;
KAPLAN MEIER METHOD;
KIDNEY TUMOR;
MORTALITY;
RANDOMIZED CONTROLLED TRIAL;
ANGIOGENESIS INHIBITORS;
CARCINOMA, RENAL CELL;
DISEASE-FREE SURVIVAL;
FOLLOW-UP STUDIES;
HUMANS;
INDOLES;
KAPLAN-MEIER ESTIMATE;
KIDNEY NEOPLASMS;
PYRIMIDINES;
PYRROLES;
SULFONAMIDES;
|
|
EID: 84899711381
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1400731 Document Type: Letter |
|
Times cited : (241)
|
|
References (2)
|
